Publication:
A middle-aged man with a troubled liver: Combination therapy in advanced (BCLC Stage C) hepatocellular carcinoma

dc.contributor.authorZamri Zuhdien_US
dc.contributor.authorAzlanuddin Azmanen_US
dc.contributor.authorAffirul Chairil Ariffinen_US
dc.contributor.authorRazman Jarminen_US
dc.contributor.authorHairol Azrin Othmanen_US
dc.date.accessioned2024-05-28T04:38:47Z
dc.date.available2024-05-28T04:38:47Z
dc.date.issued2017
dc.descriptionVolume 7, No 1en_US
dc.description.abstractAdvanced hepatocellular carcinoma carries a bad prognosis with a survival of only few months. Barcelona Clinic Liver Cancer (BCLC) Guidelines recommended sorafenib monotherapy as the treatment modality for advanced BCLC Stage C disease, citing a two-month increase in survival rates. Here, we highlight a case with advanced HCC (BCLC Stage C) treated with combination therapy of liver resection and Sorafenib therapy. The patient's current survival rate was beyond 10 months. We also discuss the current evidence on liver resection with Sorafenib therapy in hepatocellular carcinoma. The description of the case may benefit in future diagnosis and treatment.en_US
dc.identifier.doi10.5455/aces.20170503080643
dc.identifier.epage32
dc.identifier.issn2146-8133
dc.identifier.issue1
dc.identifier.spage29
dc.identifier.urihttps://oarep.usim.edu.my/handle/123456789/6005
dc.identifier.volume7
dc.language.isoen_USen_US
dc.publisherSageya Publisheren_US
dc.relation.ispartofArchives of Clinical Experimental Surgeryen_US
dc.subjectHepatocellular carcinoma, sorafenib, hepatectomyen_US
dc.titleA middle-aged man with a troubled liver: Combination therapy in advanced (BCLC Stage C) hepatocellular carcinomaen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
A middle-aged man with a troubled liver Combination therapy in advanced (BCLC Stage C) hepatocellular carcinoma.pdf
Size:
757.43 KB
Format:
Adobe Portable Document Format